NCT06851858CompletedPhase 2
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- First submitted
- 13 Feb 2025
- Start date
- 12 Mar 2025
- Primary completion date
- 26 May 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06851858
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 69
- From 12 Mar 2025 to the primary completion date, 26 May 2026
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA).
- Self-reported weight change of \> 5 % in the 3 months prior to screening.
- Use of insulin therapy for T2DM
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
Other illness
- Diabetes mellitus that is not clearly type 2 diabetes.
Lab values
- Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis)
- 8\. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening
Who the study is looking for
- Be 18 to 75 years old at the time of signing the informed consent.
- Diagnosed with type 2 diabetes ≥ 180 days before screening.
- HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol).
- On a stable maintenance dose of an injectable GLP-1 RA.
- At Screening, have a BMI ≥ 27 kg/m2
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.